Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.38 |
| ▸ | PDE4A | P27815 | 7/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9708805 | 0.92 | AGTR1 (0.40) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9707528 | 0.91 | AGTR1 (0.42) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9708255 | 0.91 | AGTR1 (0.35) | AGTR1AGTR2 | |
| SCHEMBL9707537 | 0.91 | AGTR1 (0.36) | AGTR1AGTR2 | |
| SCHEMBL9707595 | 0.90 | PDE5A (0.47) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9707858 | 0.90 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL9708051 | 0.89 | AGTR1 (0.37) | AGTR1AGTR2ADORA3 | |
| SCHEMBL9707395 | 0.89 | PDE5A (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9708131 | 0.89 | PDE5A (0.42) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9708608 | 0.89 | PDE5A (0.40) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |